Literature DB >> 35403170

Diarrhea in Placebo Arms of Cancer Studies.

Birte J Wolff1, Johannes E Wolff2.   

Abstract

Background/Aim: Diarrhea is among the most common adverse events in early oncology clinical trials, and drug causality may be difficult to determine. Materials and
Methods: This is a systematic literature review of placebo arms of randomized cancer trials.
Results: Anemia was reported in 95 of 127 placebo monotherapy cohorts. Publications involving healthy volunteers and cancer prevention studies reported lower frequencies than those with cancer patients. The average reported frequency of diarrhea grade 1 or higher among studies in cancer patients was 15%. The maximal reported frequencies for grades 1, 2, 3, 4, 5 were 56, 24, 6, 2, and 0%, respectively.
Conclusion: When higher diarrhea frequencies than those are observed in treatment arms of clinical trials, then drug causality is likely. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  Meta-analysis; adverse events; cancer; oncology; placebo; randomized; review; systematic review

Year:  2021        PMID: 35403170      PMCID: PMC8962868          DOI: 10.21873/cdp.10050

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  12 in total

1.  THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors:  A B HILL
Journal:  Proc R Soc Med       Date:  1965-05

Review 2.  Drug-induced diarrhea.

Authors:  Bincy Abraham; Joseph H Sellin
Journal:  Curr Gastroenterol Rep       Date:  2007-10

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 4.  Management of toxicities of immune checkpoint inhibitors.

Authors:  Lavinia Spain; Stefan Diem; James Larkin
Journal:  Cancer Treat Rev       Date:  2016-02-06       Impact factor: 12.111

Review 5.  Irinotecan: 25 years of cancer treatment.

Authors:  Christian Bailly
Journal:  Pharmacol Res       Date:  2019-08-12       Impact factor: 7.658

Review 6.  Headache Reporting in Oncology Trials Depends on the Demographics of the Study Population.

Authors:  Birte J Wolff; Matthaeus J Wolff; Johannes E Wolff
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

7.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Authors:  David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  Syst Rev       Date:  2015-01-01

8.  Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.

Authors:  Keun-Wook Lee; Joo Han Lim; Jee Hyun Kim; Choon-Taek Lee; Jong Seok Lee
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

9.  Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.

Authors:  Matías Rodrigo Chacón; Diego Hernán Enrico; Jeannette Burton; Federico Daniel Waisberg; Viviana Marina Videla
Journal:  JAMA Netw Open       Date:  2018-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.